Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 387

1.

Integrative Oncology Scholars Program: A Model for Integrative Oncology Education.

Zick SM, Czuhajewski C, Fouladbakhsh JM, Greenlee H, Harris RE, Henry NL, Jolly S, Khabir T, Perlmutter J, Remington T, Snyder D, Spratke L, Zebrack B, Zettell E, Benn R.

J Altern Complement Med. 2018 Sep/Oct;24(9-10):1018-1022. doi: 10.1089/acm.2018.0184.

PMID:
30247974
2.

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA.

J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242. [Epub ahead of print]

PMID:
30212295
3.

ESM-CT: a precise method for localization of DBS electrodes in CT images.

Milchenko M, Snyder AZ, Campbell MC, Dowling JL, Rich KM, Brier LM, Perlmutter JS, Norris SA.

J Neurosci Methods. 2018 Sep 7. pii: S0165-0270(18)30275-9. doi: 10.1016/j.jneumeth.2018.09.009. [Epub ahead of print]

PMID:
30201271
4.

Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques.

Shimony JS, Rutlin J, Karimi M, Tian L, Snyder AZ, Loftin SK, Norris SA, Perlmutter JS.

PLoS One. 2018 Sep 5;13(9):e0202201. doi: 10.1371/journal.pone.0202201. eCollection 2018.

5.

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; and I-SPY 2 Investigators.

NPJ Breast Cancer. 2018 Aug 17;4:26. doi: 10.1038/s41523-018-0074-6. eCollection 2018. Review.

6.

Mapping movement, mood, motivation and mentation in the subthalamic nucleus.

Gourisankar A, Eisenstein SA, Trapp NT, Koller JM, Campbell MC, Ushe M, Perlmutter JS, Hershey T, Black KJ.

R Soc Open Sci. 2018 Jul 18;5(7):171177. doi: 10.1098/rsos.171177. eCollection 2018 Jul.

7.

Selective D2 receptor PET in manganese-exposed workers.

Criswell SR, Warden MN, Searles Nielsen S, Perlmutter JS, Moerlein SM, Sheppard L, Lenox-Krug J, Checkoway H, Racette BA.

Neurology. 2018 Sep 11;91(11):e1022-e1030. doi: 10.1212/WNL.0000000000006163. Epub 2018 Aug 10.

PMID:
30097475
8.

Exploration of Sulfur-Containing Analogues for Imaging Vesicular Acetylcholine Transporter in the Brain.

Luo Z, Liu H, Jin H, Gu J, Yu Y, Kaneshige K, Perlmutter JS, Parsons SM, Tu Z.

ChemMedChem. 2018 Sep 19;13(18):1978-1987. doi: 10.1002/cmdc.201800411. Epub 2018 Aug 19.

PMID:
30071131
9.

Suicidal Ideation Assessment in Individuals with Premanifest and Manifest Huntington Disease.

Wesson M, Boileau NR, Perlmutter JS, Paulsen JS, Barton SK, McCormack MK, Carlozzi NE.

J Huntingtons Dis. 2018;7(3):239-249. doi: 10.3233/JHD-180299.

PMID:
30056431
10.

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Kirshner JJ, Krop IE, Levinson J, Modi S, Patt DA, Perlmutter J, Winer EP, Lin NU.

J Clin Oncol. 2018 Sep 20;36(27):2804-2807. doi: 10.1200/JCO.2018.79.2713. Epub 2018 Jun 25.

PMID:
29939840
11.

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, Modi S, Patt DA, Perlmutter J, Ramakrishna N, Winer EP, Davidson NE.

J Clin Oncol. 2018 Sep 10;36(26):2736-2740. doi: 10.1200/JCO.2018.79.2697. Epub 2018 Jun 25.

PMID:
29939838
12.

Consensus-Based Attributes for Identifying Patients With Spasmodic Dysphonia and Other Voice Disorders.

Ludlow CL, Domangue R, Sharma D, Jinnah HA, Perlmutter JS, Berke G, Sapienza C, Smith ME, Blumin JH, Kalata CE, Blindauer K, Johns M, Hapner E, Harmon A, Paniello R, Adler CH, Crujido L, Lott DG, Bansberg SF, Barone N, Drulia T, Stebbins G.

JAMA Otolaryngol Head Neck Surg. 2018 Aug 1;144(8):657-665. doi: 10.1001/jamaoto.2018.0644.

PMID:
29931028
13.

Microbial Misandry: Discovery of a Spiroplasma Male-Killing Toxin.

Perlmutter JI, Bordenstein SR.

Cell Host Microbe. 2018 Jun 13;23(6):689-690. doi: 10.1016/j.chom.2018.05.011.

PMID:
29902429
14.

Emergent Functional Network Effects in Parkinson Disease.

Gratton C, Koller JM, Shannon W, Greene DJ, Snyder AZ, Petersen SE, Perlmutter JS, Campbell MC.

Cereb Cortex. 2018 Jun 6. doi: 10.1093/cercor/bhy121. [Epub ahead of print]

PMID:
29878081
15.

Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease.

Ibanez L, Dube U, Davis AA, Fernandez MV, Budde J, Cooper B, Diez-Fairen M, Ortega-Cubero S, Pastor P, Perlmutter JS, Cruchaga C, Benitez BA.

Front Neurosci. 2018 Apr 10;12:230. doi: 10.3389/fnins.2018.00230. eCollection 2018.

16.

Agreement between clinician-rated versus patient-reported outcomes in Huntington disease.

Carlozzi NE, Boileau NR, Perlmutter JS, Chou KL, Stout JC, Paulsen JS, McCormack MK, Cella D, Nance MA, Lai JS, Dayalu P.

J Neurol. 2018 Jun;265(6):1443-1453. doi: 10.1007/s00415-018-8852-5. Epub 2018 Apr 23.

PMID:
29687215
17.

Cervical dystonia and substance abuse.

Mahajan A, Jankovic J, Marsh L, Patel A, Jinnah HA, Comella C, Barbano R, Perlmutter J, Patel N; members of the Dystonia Coalition.

J Neurol. 2018 Apr;265(4):970-975. doi: 10.1007/s00415-018-8840-9. Epub 2018 Mar 22.

PMID:
29569175
18.

Relationships Among Apathy, Health-Related Quality of Life, and Function in Huntington's Disease.

Fritz NE, Boileau NR, Stout JC, Ready R, Perlmutter JS, Paulsen JS, Quaid K, Barton S, McCormack MK, Perlman SL, Carlozzi NE; Huntington Disease Quality of Life Site Investigators and Coordinators, University of Michigan, University of Iowa, Indiana University, Johns Hopkins University, University of California, Rutgers University, Piscataway, Washington University, Struthers Parkinson’s Center, Cleveland Clinic Foundation, University of California, Northwestern University.

J Neuropsychiatry Clin Neurosci. 2018 Summer;30(3):194-201. doi: 10.1176/appi.neuropsych.17080173. Epub 2018 Mar 21.

PMID:
29558861
19.

Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline.

Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, Halberg F, Hoffman K, Horst K, Moran J, Patton C, Perlmutter J, Warren L, Whelan T, Wright JL, Jagsi R.

Pract Radiat Oncol. 2018 May - Jun;8(3):145-152. doi: 10.1016/j.prro.2018.01.012. Epub 2018 Mar 12.

PMID:
29545124
20.

Pharmacokinetics and Toxicology of the Neuroprotective e,e,e-Methanofullerene(60)-63-tris Malonic Acid [C3] in Mice and Primates.

Hardt JI, Perlmutter JS, Smith CJ, Quick KL, Wei L, Chakraborty SK, Dugan LL.

Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):543-554. doi: 10.1007/s13318-018-0464-z.

PMID:
29520718
21.

Physical therapy and deep brain stimulation in Parkinson's Disease: protocol for a pilot randomized controlled trial.

Duncan RP, Van Dillen LR, Garbutt JM, Earhart GM, Perlmutter JS.

Pilot Feasibility Stud. 2018 Feb 21;4:54. doi: 10.1186/s40814-018-0243-2. eCollection 2018.

22.

Quantitative, clinically relevant acoustic measurements of focal embouchure dystonia.

Morris AE, Norris SA, Perlmutter JS, Mink JW.

Mov Disord. 2018 Mar;33(3):449-458. doi: 10.1002/mds.27298. Epub 2018 Feb 20.

PMID:
29460980
23.

In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.

Liu H, Jin H, Luo Z, Yue X, Zhang X, Flores H, Su Y, Perlmutter JS, Tu Z.

ACS Chem Neurosci. 2018 May 16;9(5):1066-1073. doi: 10.1021/acschemneuro.7b00458. Epub 2018 Feb 19.

PMID:
29400443
24.

7T MRI subthalamic nucleus atlas for use with 3T MRI.

Milchenko M, Norris SA, Poston K, Campbell MC, Ushe M, Perlmutter JS, Snyder AZ.

J Med Imaging (Bellingham). 2018 Jan;5(1):015002. doi: 10.1117/1.JMI.5.1.015002. Epub 2018 Jan 8.

PMID:
29340288
25.

Kinetic modeling of [18 F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain.

Jin H, Yue X, Liu H, Han J, Flores H, Su Y, Parsons SM, Perlmutter JS, Tu Z.

J Neurochem. 2018 Mar;144(6):791-804. doi: 10.1111/jnc.14291. Epub 2018 Mar 25.

PMID:
29315563
26.

Synthesis and in vitro characterization of a P2X7 radioligand [123I]TZ6019 and its response to neuroinflammation in a mouse model of Alzheimer disease.

Jin H, Han J, Resing D, Liu H, Yue X, Miller RL, Schoch KM, Miller TM, Perlmutter JS, Egan TM, Tu Z.

Eur J Pharmacol. 2018 Feb 5;820:8-17. doi: 10.1016/j.ejphar.2017.12.006. Epub 2017 Dec 7.

PMID:
29225193
27.

A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning.

Carlozzi NE, Hahn EA, Frank SA, Perlmutter JS, Downing ND, McCormack MK, Barton S, Nance MA, Schilling SG; HDQLIFE Site Investigators and Coordinators.

J Neurol. 2018 Jan;265(1):98-107. doi: 10.1007/s00415-017-8677-7. Epub 2017 Nov 15.

PMID:
29143208
28.

Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels.

Ibanez L, Dube U, Saef B, Budde J, Black K, Medvedeva A, Del-Aguila JL, Davis AA, Perlmutter JS, Harari O, Benitez BA, Cruchaga C.

BMC Neurol. 2017 Nov 15;17(1):198. doi: 10.1186/s12883-017-0978-z.

29.

ACR Appropriateness Criteria® Cranial Neuropathy.

Expert Panel on Neurologic Imaging:, Policeni B, Corey AS, Burns J, Conley DB, Crowley RW, Harvey HB, Hoang J, Hunt CH, Jagadeesan BD, Juliano AF, Kennedy TA, Moonis G, Pannell JS, Patel ND, Perlmutter JS, Rosenow JM, Schroeder JW, Whitehead MT, Cornelius RS.

J Am Coll Radiol. 2017 Nov;14(11S):S406-S420. doi: 10.1016/j.jacr.2017.08.035.

PMID:
29101981
30.

Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?

Jinnah HA, Comella CL, Perlmutter J, Lungu C, Hallett M; Dystonia Coalition Investigators.

Toxicon. 2018 Jun 1;147:89-95. doi: 10.1016/j.toxicon.2017.09.004. Epub 2017 Sep 6. Review.

PMID:
28888929
31.

Adult-onset dystonia with marfanoid features.

Norris SA, Pogarcic A, Hicks M, Perlmutter JS, Shinawi M.

Neurol Clin Pract. 2017 Aug;7(4):e31-e34. doi: 10.1212/CPJ.0000000000000297. No abstract available.

32.

[18F]FDOPA positron emission tomography in manganese-exposed workers.

Criswell SR, Nielsen SS, Warden M, Perlmutter JS, Moerlein SM, Flores HP, Huang J, Sheppard L, Seixas N, Checkoway H, Racette BA.

Neurotoxicology. 2018 Jan;64:43-49. doi: 10.1016/j.neuro.2017.07.004. Epub 2017 Jul 8.

PMID:
28694016
33.

Factors Associated With End-of-Life Planning in Huntington Disease.

Downing NR, Goodnight S, Chae S, Perlmutter JS, McCormack M, Hahn E, Barton SK, Carlozzi N.

Am J Hosp Palliat Care. 2018 Mar;35(3):440-447. doi: 10.1177/1049909117708195. Epub 2017 Jun 28.

PMID:
28655280
34.

Synthesis, resolution, and in vitro evaluation of three vesicular acetylcholine transporter ligands and evaluation of the lead fluorine-18 radioligand in a nonhuman primate.

Yue X, Jin H, Liu H, Luo Z, Zhang X, Kaneshige K, Flores HP, Perlmutter JS, Parsons SM, Tu Z.

Org Biomol Chem. 2017 Jun 21;15(24):5197-5209. doi: 10.1039/c7ob00854f.

35.

Research Priorities in Limb and Task-Specific Dystonias.

Pirio Richardson S, Altenmüller E, Alter K, Alterman RL, Chen R, Frucht S, Furuya S, Jankovic J, Jinnah HA, Kimberley TJ, Lungu C, Perlmutter JS, Prudente CN, Hallett M.

Front Neurol. 2017 May 3;8:170. doi: 10.3389/fneur.2017.00170. eCollection 2017. Review.

36.

Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.

Calis KA, Archdeacon P, Bain R, DeMets D, Donohue M, Elzarrad MK, Forrest A, McEachern J, Pencina MJ, Perlmutter J, Lewis RJ.

Clin Trials. 2017 Aug;14(4):342-348. doi: 10.1177/1740774517707743. Epub 2017 May 13.

37.

ACR Appropriateness Criteria® Cerebrovascular Disease.

Expert Panel on Neurologic Imaging:, Salmela MB, Mortazavi S, Jagadeesan BD, Broderick DF, Burns J, Deshmukh TK, Harvey HB, Hoang J, Hunt CH, Kennedy TA, Khalessi AA, Mack W, Patel ND, Perlmutter JS, Policeni B, Schroeder JW, Setzen G, Whitehead MT, Cornelius RS, Corey AS.

J Am Coll Radiol. 2017 May;14(5S):S34-S61. doi: 10.1016/j.jacr.2017.01.051. Review.

PMID:
28473091
38.

TMEM230 in Parkinson's disease.

Ibanez L, Dube U, Budde J, Black K, Medvedeva A, Davis AA, Perlmutter JS, Benitez BA, Cruchaga C.

Neurobiol Aging. 2017 Aug;56:212.e1-212.e3. doi: 10.1016/j.neurobiolaging.2017.03.014. Epub 2017 Mar 16.

39.

Psychiatric associations of adult-onset focal dystonia phenotypes.

Berman BD, Junker J, Shelton E, Sillau SH, Jinnah HA, Perlmutter JS, Espay AJ, Jankovic J, Vidailhet M, Bonnet C, Ondo W, Malaty IA, Rodríguez R, McDonald WM, Marsh L, Zurowski M, Bäumer T, Brüggemann N.

J Neurol Neurosurg Psychiatry. 2017 Jul;88(7):595-602. doi: 10.1136/jnnp-2016-315461. Epub 2017 Apr 24.

40.

Pharmacologic characterizations of a P2X7 receptor-specific radioligand, [11C]GSK1482160 for neuroinflammatory response.

Han J, Liu H, Liu C, Jin H, Perlmutter JS, Egan TM, Tu Z.

Nucl Med Commun. 2017 May;38(5):372-382. doi: 10.1097/MNM.0000000000000660.

41.

Striatal molecular imaging of presynaptic markers: Ready, fire, aim.

Takeda A, Perlmutter JS.

Neurology. 2017 Apr 11;88(15):1388-1389. doi: 10.1212/WNL.0000000000003827. Epub 2017 Mar 10. No abstract available.

PMID:
28283591
42.

Pathologic correlates of supranuclear gaze palsy with parkinsonism.

Martin WRW, Hartlein J, Racette BA, Cairns N, Perlmutter JS.

Parkinsonism Relat Disord. 2017 May;38:68-71. doi: 10.1016/j.parkreldis.2017.02.027. Epub 2017 Feb 24.

43.

Prophage WO genes recapitulate and enhance Wolbachia-induced cytoplasmic incompatibility.

LePage DP, Metcalf JA, Bordenstein SR, On J, Perlmutter JI, Shropshire JD, Layton EM, Funkhouser-Jones LJ, Beckmann JF, Bordenstein SR.

Nature. 2017 Mar 9;543(7644):243-247. doi: 10.1038/nature21391. Epub 2017 Feb 27.

44.

Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.

Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T, Piccini P, Politis M, Thobois S, Ceravolo R, Higuchi M, Kaasinen V, Masellis M, Peralta MC, Obeso I, Pineda-Pardo JÁ, Cilia R, Ballanger B, Niethammer M, Stoessl JA; IPMDS-Neuroimaging Study Group.

Mov Disord. 2017 Feb;32(2):181-192. doi: 10.1002/mds.26907. Epub 2017 Feb 2. Review.

PMID:
28150432
45.

Chiral resolution of serial potent and selective σ1 ligands and biological evaluation of (-)-[18F]TZ3108 in rodent and the nonhuman primate brain.

Yue X, Jin H, Luo Z, Liu H, Zhang X, McSpadden ED, Tian L, Flores HP, Perlmutter JS, Parsons SM, Tu Z.

Bioorg Med Chem. 2017 Feb 15;25(4):1533-1542. doi: 10.1016/j.bmc.2017.01.017. Epub 2017 Jan 16.

46.

Absorbed radiation dosimetry of the D3-specific PET radioligand [18F]FluorTriopride estimated using rodent and nonhuman primate.

Laforest R, Karimi M, Moerlein SM, Xu J, Flores HP, Bognar C, Li A, Mach RH, Perlmutter JS, Tu Z.

Am J Nucl Med Mol Imaging. 2016 Nov 30;6(6):301-309. eCollection 2016.

47.

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators.

Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2.

48.

Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.

Eisenstein SA, Bogdan R, Chen L, Moerlein SM, Black KJ, Perlmutter JS, Hershey T, Barch DM.

J Psychiatr Res. 2017 Mar;86:9-17. doi: 10.1016/j.jpsychires.2016.11.007. Epub 2016 Nov 17.

49.

Understanding the functions and operations of data monitoring committees: Survey and focus group findings.

Calis KA, Archdeacon P, Bain RP, Forrest A, Perlmutter J, DeMets DL.

Clin Trials. 2017 Feb;14(1):59-66. doi: 10.1177/1740774516679665. Epub 2016 Nov 24.

PMID:
27885056
50.

Sex-specific effects of the Huntington gene on normal neurodevelopment.

Lee JK, Ding Y, Conrad AL, Cattaneo E, Epping E, Mathews K, Gonzalez-Alegre P, Cahill L, Magnotta V, Schlaggar BL, Perlmutter JS, Kim RE, Dawson JD, Nopoulos P.

J Neurosci Res. 2017 Jan 2;95(1-2):398-408. doi: 10.1002/jnr.23980.

Supplemental Content

Loading ...
Support Center